Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3/FCRL6 engagement
Douglas B. Johnson(Vanderbilt University), Justin M. Balko(Vanderbilt University Medical Center)
Cited by 159
Related Papers
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|570
MEK inhibition activates STAT signaling to increase breast cancer immunogenicity via MHC-I expression
|Cancer Drug Resistance|2020|28
The genomic map of breast cancer: which roads lead to better targeted therapies?
|Breast Cancer Research|2013|10